Key result
Combined chemo-radiotherapy halts prostate rhabdomyosarcoma progression for ~1 year in a young adult.
Why the study?
Primary rhabdomyosarcoma of the adult prostate is rare and associated with poor prognosis despite combined modality therapy improving outcomes in children.
Case Report (n=1)
Combined-modality treatment including chemotherapy and radiotherapy provided about 1 year of progression-free survival in a young adult with rare prostate rhabdomyosarcoma.
May support combined modality in rare prostate rhabdomyosarcoma; leaves open prospective validation before practice change.
Primary rhabdomyosarcoma of the adult prostate is rare and associated with an aggressive clinical course. Combined modality therapy has resulted in marked improvement in survival rates and reduced surgical morbidity for children with these tumors. However, in adults the prognosis remains poor.We report on a case of prostate rhabdomyosarcoma in an adult approached with combined-modality treatment, with the administration of 9 courses of doxorubicin, vincristine and endoxan, and, subsequent radiotherapy to the prostaticbed. The patient remained free of progression of disease for about 1 year.
No takes yet. Share an insight, caveat, or question.
Sow et al. (2021) conducted a case report in Prostate rhabdomyosarcoma (n=1). Combined-modality treatment (doxorubicin, vincristine, endoxan, and radiotherapy) was evaluated on Progression of disease. Combined-modality treatment with chemotherapy and radiotherapy in a young adult with prostate rhabdomyosarcoma resulted in the patient remaining free of disease progression for about 1 year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: